Genetics of hypertrophic cardiomyopathy: advances and pitfalls in molecular diagnosis and therapy

Catarina Roma-Rodrigues¹
Alexandra R Fernandes¹,²
¹UCiBiO, Departamento de Ciências da Vida, Faculdade de Ciências e Tecnologia da Universidade Nova de Lisboa, Campus de Caparica, Caparica, Portugal; ²Centro de Química Estrutural, Instituto Superior Técnico, Universidade de Lisboa, Lisboa, Portugal

Abstract: Hypertrophic cardiomyopathy (HCM) is a primary disease of the cardiac muscle that occurs mainly due to mutations (>1,400 variants) in genes encoding for the cardiac sarcomere. HCM, the most common familial form of cardiomyopathy, affecting one in every 500 people in the general population, is typically inherited in an autosomal dominant pattern, and presents variable expressivity and age-related penetrance. Due to the morphological and pathological heterogeneity of the disease, the appearance and progression of symptoms is not straightforward. Most HCM patients are asymptomatic, but up to 25% develop significant symptoms, including chest pain and sudden cardiac death. Sudden cardiac death is a dramatic event, since it occurs without warning and mainly in younger people, including trained athletes. Molecular diagnosis of HCM is of the utmost importance, since it may allow detection of subjects carrying mutations on HCM-associated genes before development of clinical symptoms of HCM. However, due to the genetic heterogeneity of HCM, molecular diagnosis is difficult. Currently, there are mainly four techniques used for molecular diagnosis of HCM, including Sanger sequencing, high resolution melting, mutation detection using DNA arrays, and next-generation sequencing techniques. Application of these methods has proven successful for identification of mutations on HCM-related genes. This review summarizes the features of these technologies, highlighting their strengths and weaknesses. Furthermore, current therapeutics for HCM patients are correlated with clinically observed phenotypes and are based on the alleviation of symptoms. This is mainly due to insufficient knowledge on the mechanisms involved in the onset of HCM. Tissue engineering alongside regenerative medicine coupled with nanotherapeutics may allow fulfillment of those gaps, together with screening of novel therapeutic drugs and target delivery systems.

Keywords: hypertrophic cardiomyopathy, molecular diagnosis, sarcomere, next-generation sequencing, sudden cardiac death

Introduction
Cardiomyopathies are a heterogeneous group of diseases affecting the heart muscle and frequently lead to progressive heart failure-related disability or cardiovascular death.¹,² According to the morphological and functional phenotype, cardiomyopathies can be divided in hypertrophic cardiomyopathy (HCM), dilated cardiomyopathy, restrictive left ventricular cardiomyopathy, arrhythmogenic cardiomyopathy, and left ventricular non-compaction.¹,² A detailed definition and description of the subtypes of cardiomyopathies is outside the scope of this review and may be found elsewhere.¹-³ Many cardiomyopathies are monogenic disorders due to single gene mutations in germinal cells and thereby are inherited.³ HCM, a primary disease of the cardiac muscle that
occurs mainly due to mutations in genes encoding for the cardiac contractile apparatus, is the most common familial form of cardiomyopathy, as well as the most phenotypically variable cardiac disease.\textsuperscript{1–6} Indeed, the pathophysiology of HCM is complex, being characterized by a wide range of disease processes, with varying genetics, clinical manifestations, heart morphology, and prognosis.\textsuperscript{6} Due to the phenotypic heterogeneity of the disease, the diagnosis of HCM at late adulthood is frequent, when the morphology and functional debility of the heart caused by the disease have progressed.\textsuperscript{7} This is of special importance for asymomatic or mildly symptomatic young patients with HCM who may experience ventricular arrhythmias and sudden cardiac death.\textsuperscript{9} The molecular diagnosis of HCM allows the detection of subjects carrying a mutation on genes that cause the disease, even before the development of symptoms.\textsuperscript{9} This review outlines the current knowledge about HCM, describing the biochemistry and physiology of HCM, highlighting the genetic and allelic heterogeneity underlying HCM, and pointing out the methods used for molecular diagnosis of HCM, along with their advantages and current limitations. It also emphasizes the current and new directions in HCM therapy.

**Hypertrophic cardiomyopathy**

**Physiology and biochemistry of the normal heart – what goes wrong!**

The mechanical events that allow a cardiac cycle to occur require an appropriate venous return, regulation of outflow resistance, a normal myocardial contractile state, heart rate control, and an adequate supply of oxygenated blood.\textsuperscript{10} Alterations in one of these aspects may lead to cardiac deficiency.\textsuperscript{10} In HCM, the myocardial contractile state is compromised by cardiomyocyte hypertrophy, disarray, and increased myocardial fibrosis.\textsuperscript{6} In fact, the myocardium of a heart affected by HCM is composed of myocytes with distorted nuclei and disorganized myofibrils.\textsuperscript{11} This morphology have a negative impact on cardiac relaxation and lead to arrhythmias and progression of heart failure.\textsuperscript{11}

Despite the limited knowledge of the mechanisms involved in modification of cardiomyocytes in HCM, it is well established that they are related to mutations at the level of the sarcomere proteins and other proteins involved in muscle contraction and force transduction.\textsuperscript{6} Sarcomeres, which are responsible for muscle contraction, are formed by contractile myofibrils composed of thick filaments (myosin) and thin filaments (actin and associated regulatory proteins, ie, tropomyosin and troponins C, I, and T) that slide past each other (Figure 1).\textsuperscript{12–13} Other proteins involved in the maintenance and regulation of sarcomere structure and function include myosin binding protein (MyBP)-c, titin, and troponysin.\textsuperscript{13} Several mitochondria, which are responsible for generation of adenosine triphosphate for contraction, are scattered between myofibrils.\textsuperscript{12} Electrical excitation of the myocyte results in a high increase in the intracellular calcium concentration, an event called excitation-contraction coupling, that initiates further release of calcium from the sarcoplasmic reticulum.\textsuperscript{2,13} Contractions of the sarcomere are then initiated by calcium binding to troponin C, enabling projections of the myosin molecules to interact with actin molecules, through an adenosine triphosphate-dependent process.\textsuperscript{12,13} Relaxation occurs by lowering the calcium concentration in the myocyte and consequent detachment from troponin C.\textsuperscript{12} In HCM, mutations occurring at the level of the sarcomere will ultimately result in inefficient or excessive use of adenosine triphosphate and therefore in an energy deficiency.\textsuperscript{7,14} Among other consequences, these energy requirements compromise calcium homeostasis and excitation-contraction coupling, in turn compromising the relaxation capacity of the cardiomyocytes and consequently the force of contractibility.\textsuperscript{7,15} Moreover, mutations in sarcomere proteins seem to trigger an early increase in the synthesis of collagen, which will result in myocardial fibrosis and consequently in overt HCM.\textsuperscript{16} Myocardial fibrosis, together with an increase in the size of cardiomyocytes, results in myocardial left ventricular hypertrophy (LVH; Figure 2).\textsuperscript{11}

**Physiological and morphological characteristics**

Myocardial fibrosis in HCM patients seems to be related to the myocyte death caused by stresses imposed by sarcomere mutations.\textsuperscript{16} Due to the limited division of cardiomyocytes, maintenance of the structural integrity of the heart is accomplished by accumulation of fibroblasts.\textsuperscript{17} However, because fibroblasts do not have a contractile capacity, a supplementary effort is required from the surviving cardiomyocytes and a consequent downward spiral that includes neurohormonal activation, further cardiomyocyte death, and increased fibrosis.\textsuperscript{17,18} Myocardial fibrosis and further ischemia may result in LVH and predispose patients to ventricular arrhythmias and ultimately to sudden cardiac death.\textsuperscript{16} This clinical outcome occurs unexpectedly, mainly in young people, including trained athletes.\textsuperscript{8,19} LVH is highly age-dependent, mainly occurring during or soon after the periods of rapid somatic growth that take place during puberty.\textsuperscript{7,20}
Advances in molecular diagnosis of hypertrophic cardiomyopathy

HCM is generally characterized at the morphological level by a thickening of the left ventricular wall (Figure 2), usually ≥15 mm, and a consequent decrease in left ventricular chamber size. Although asymmetric septal hypertrophy is most common, there is significant heterogeneity in the degree and pattern of LVH. Due to the morphological and pathological heterogeneity of the disease, the appearance and progression of symptoms is not straightforward. Most HCM patients are asymptomatic, but up to 25% will develop significant symptoms, including chest pain and/or heart failure up to heart transplant. Recent work has suggested a correlation between mortality and age, with an inverse relationship being observed between age and sudden death, and a direct relationship between age and stroke-related death. Arrhythmias occur in approximately 20% of HCM patients, leading to a poorer prognosis, as these patients have a higher probability of suffering stroke and heart failure. Furthermore, the clinical outcomes that may develop in HCM patients include systolic anterior motion of the mitral valve with associated obstruction of left ventricular outflow and mitral regurgitation, mid ventricular obstruction as a result of systolic cavity obliteration, and an intracavitary subvalvular dynamic gradient. HCM patients must be monitored lifelong by a cardiologist. Clinical diagnosis of HCM requires a hypertrophied, non-dilated left ventricle without evidence of any other cardiac or systemic disease (eg, systemic hypertension or aortic valve stenosis) that could produce the extent of hypertrophy evident. Indications of HCM can be seen on an electrocardiogram, although the diagnosis is based on

Figure 1 Schematic representation of heart failure due to sarcomeric/intrasarcomeric mutations. Mutations in the proteins responsible for the maintenance of sarcomere structure and function result in inefficient or excessive use of ATP and a consequent energy deficiency. The energy requirements then compromise calcium homeostasis in the cell, resulting in, among other events, an increase in calcium sensitivity of the ATPase SERCA and increased cytosolic free calcium. The contractibility of the myocyte is then compromised, ultimately resulting in cell death and consequent myocardial fibrosis. This myocardial fibrosis and further ischemia may result in left ventricular hypertrophy, increasing the risk of heart failure.

Abbreviations: NCX, sodium–calcium exchanger; DHPR, dihydropyridine receptor; Ryr, ryanodine receptor; SERCA, sarco/endoplasmic reticulum Ca2+-ATPase; AMP, adenosine monophosphate; ATP, adenosine triphosphate.
an echocardiogram and/or magnetic resonance imaging. However, identification of LVH on an echocardiogram or magnetic resonance imaging cannot be uniquely associated with HCM, also due to the existence of HCM phenocopies. Indeed, a differential diagnosis of HCM is required to discard a LVH associated with metabolic and multiorgan genetic syndromes (eg, amyloidosis, cardiac-specific glycogen storage disease, Noonan syndrome, Danon disease, Anderson-Fabry disease, or Friedrich's ataxia). The treatment (medication, surgical or percutaneous septum reduction, and/or internal cardioverter defibrillator implantation) is determined based on the symptoms and the stratification risk for sudden cardiac death. Indeed, the management of HCM patients is directed at control of heart failure symptoms, prevention of sudden cardiac death, treatment of atrial fibrillation, and screening of family members. Around 70% of HCM patients have dynamic left ventricular outflow obstruction at rest or provoked by exercise, and 10% of these patients will progress and require therapeutic intervention.

**Genetic causes**

From the genetic point of view, more than 90% of HCM is inherited as an autosomal dominant disease with variable expressivity and age-related penetrance, affecting one in every 500 people in the general population. Hence, the offspring of an affected individual have a 50% probability of inheriting a mutation and risk for HCM. Furthermore, a recent study identified a mutation in the gene encoding the four-and-a-half LIM domain 1 (FHL1) responsible for HCM, suggesting an X-linked inheritance. Alternatively, sporadic HCM cases may be due to de novo mutations in the proband (absent in the parents). Sixty percent of the mutations occurring in sarcomere genes were described as familial HCM. Moreover, 5% of patients with familial HCM are heterozygous carriers, carrying up to three distinct mutations that are associated with a poorer prognosis. In addition, the phenotypic heterogeneity of HCM within families suggests an environmental role in onset of the disease; for example, obesity seems to increase the thickness of the myocardium and to have an impact on the development of LVH and pathology.

Interestingly, a pattern of variability can be distinguished in the types of mutations causing HCM among worldwide populations. While in north European and Southeast Asia Indian populations, HCM is mainly due to founding mutations and hence familial HCM, in the rest of the world a marked heterogeneity in HCM-associated mutations is observed.

**Genes and mutations**

To date, around 1,400 mutations have been identified as being responsible for HCM pathology (Table 1). About 70% of these mutations are in the sarcomere genes encoding cardiac β-myosin heavy chain (MYH7) and cardiac myosin binding protein C (MYBPC3), as shown in Table 1. Other sarcomeric genes, eg, regulatory myosin light chain (MYL2), cardiac troponin T (TNNT2), cardiac troponin I (TNNI3), and actin (ACTC), and non-sarcomeric genes, such as genes encoding plasma membrane and mitochondrial proteins, as well as sarcomere adjacent Z-disc encoding genes, account for the other cases (Table 1).

Ultimately, the effect of a mutation on the contraction of the cardiac muscle will depend on the mutated gene, the location of the mutation within the gene, and consequently on the protein and the abundance of the mutated protein within the myocyte. The mutations occurring in most part of sarcomere encoding genes are missense with a dominant negative effect resulting in the formation of poison polypeptides incorporated into the sarcomere, with consequences for its function. However, most MYBPC3 mutations are predicted to result in frame shift and often in protein truncation. Incorporation of the truncated forms in the sarcomere results in disruption of the normal sarcomeric structure and in partial haploinsufficiency.

Due to heterogeneity, age dependence, and incomplete penetrance, the concept of genotype-phenotype has not been established for HCM. Nevertheless, some TNNT2 mutations have been related to minor LVH and an appreciable risk of arrhythmia. Additionally, some mutations in the MYH7 gene result in significant LVH after the second decade of life and seem to be associated with sudden cardiac death; on the other hand, it has been suggested that variants of MYBPC3 are associated with later onset of HCM.

A mutation can be considered pathogenic on the basis of the following criteria: cosegregation with the HCM phenotype (eg, LVH) in family members; previously reported...
Table 1 Hypertrophic cardiomyopathy-associated genes, proteins, and number of mutations described for each gene (protein location or function is also described)

| Gene    | Chromosomal position | Protein | HCM-associated mutations | Location or function          |
|---------|-----------------------|---------|--------------------------|-------------------------------|
| ACTA1   | 1q42.13–q42.2         | Actin, alpha 1 | 1 | Sarcomere, skeletal muscle |
| ACTC1   | 15q11–q14             | Actin, alpha, cardiac muscle 1 | 25 | Sarcomere, cardiac muscle |
| ACTN2   | 1q42–q43              | Actin, alpha 2 | 5 | Z-disk |
| ANKRD1  | 10q23.33              | Ankyrin repeat domain 1 | 3 | Z-disk and nucleus (transcription factor) |
| BRAF    | 7q34                  | v-Raf murine sarcoma viral oncogene homolog B1 | 1 | Cytoplasmic serine/threonine kinase |
| COAS    | 2q11.2                | Cytochrome c oxidase assembly factor 5 | 1 | Mitochondrial |
| CALM3   | 19q13.2–q13.3         | Calmodulin 3 (phosphorylase kinase, delta) | 1 | Calcium sensor and signal transducer |
| CALR3   | 19p13.11              | Calreticulin 3 | 2 | Endoplasmic reticulum chaperone |
| CASQ2   | 1p13.3–p11            | Calsequestrin 2 | 1 | Sarcoplasmic reticulum; calcium storage |
| CAV3    | 3p25                  | Caveolin 3 | 1 | Plasma membrane |
| COX15   | 10q24                 | Cytochrome c oxidase assembly homolog 15 | 2 | Mitochondrial respiratory chain |
| CSRP3   | 11p15.1               | Cysteine and glycine-rich protein 3 | 15 | Z-disk |
| DES     | 2q35                  | Desmin | 1 | Intermediate filament |
| FHL1    | Xq26                  | Four and a half LIM domains | 3 | Biomechanical stress sensor |
| FHOD3   | 18q12                 | Formin homology 2 domain containing 3 | 1 | Actin-organizing protein |
| FXN     | 9q13–q21.1            | Frataxin | 1 | Mitochondrial iron transport and respiration |
| GLA     | Xq22                  | Galactosidase, alpha | 765 | Lysosome |
| JPH2    | 20q13.12              | Junctophilin 2 | 6 | Junctional membrane complexes; calcium signaling |
| KLF10   | 8q22.2                | Kruppel-like factor 10 | 6 | Transcriptional repressor; inhibits cell growth |
| MAP2K1  | 15q22.1–q22.33        | Mitogen-activated protein kinase kinase 1 | 1 | MAP kinase kinase; signal transduction |
| MAP2K2  | 19p13.3               | Mitogen-activated protein kinase kinase 2 | 1 | MAP kinase kinase; signal transduction |
| MRPL3   | 3q21–q23              | Mitochondrial ribosomal protein L3 | 1 | Mitochondrial ribosomal protein |
| MTO1    | 6q13                  | Mitochondrial tRNA translation optimization 1 | 2 | Mitochondrial tRNA modification |
| MYBP3   | 11p11.2               | Myosin binding protein C, cardiac | 506 | Sarcomere |
| MTH6    | 14q12                 | Alpha-myosin heavy chain | 3 | Sarcomere |
| MTH7    | 14q12                 | Beta-myosin heavy chain | 491 | Sarcomere |
| MYLK2   | 12q23–q24.3           | Ventricular myosin regulatory light chain | 20 | Sarcomere |
| MYL3    | 3p21.3–p21.2          | Myosin light chain 3 | 16 | Sarcomere |
| MYLF2   | 20q13.31              | Myosin light chain kinase 2 | 2 | Calcium/calmodulin-dependent kinase |
| MYO6    | 6q13                  | Myosin VI | 1 | Actin-based reverse-direction motor protein |
| MYOM1   | 18p11.31              | Myomesin 1 | 1 | Sarcomere |
| MYOZ2   | 4q26–q27              | Myozin 2 | 2 | Z-disk |
| MYPN    | 10q21.3               | Myopalladin | 8 | Z-disk |
| NDUFA1  | 15q11.2–q21.3         | NADH dehydrogenase (ubiquinone) complex I, assembly factor 1 | 2 | Mitochondrial chaperone |
| NDUFA2  | 18p11.31–p11.2        | NADH dehydrogenase (ubiquinone) flavoprotein 2 | 1 | Mitochondrial respiratory chain |
| NEXN    | 1p31.1                | Nexilin | 2 | Z-disk |
| OBSCN   | 1q42.13               | Obscurin | 1 | Sarcomere |
| PDLIM3  | 4q35                  | PDZ and LIM domain 3 | 1 | Z-disk |
| PRKAG2  | 7q36.1                | 5’-AMP-activated protein kinase subunit gamma-2 | 7 | Energy sensor protein kinase |
| PLN     | 6q22.1                | Phospholamban | 7 | Sarcomplasmic reticulum; regulates Ca2+-ATPase |

(Continued)
Table 1 (Continued)

| Gene | Chromosomal position | Protein | HCM-associated mutations | Location or function |
|------|----------------------|---------|--------------------------|----------------------|
| RAF1 | 3p25                 | v-Raf-1 murine leukemia viral oncogene homolog 1 | 1                     | Serine/threonine-protein kinase; signal transduction |
| SLC25A3 | 12q23             | Solute carrier family 25, member 3 | 1                     | Phosphate carrier protein (cytosol to mitochondria) |
| SLC25A4 | 4q35               | Solute carrier family 25, member 4 | 2                     | Adenine nucleotide translocator (cytosol/mitochondria) |
| SOS1 | 2p22–p23           | Son of sevenless homolog 1 | 1                     | Guanine nucleotide exchange factor for RAS proteins; signal transduction |
| SRI  | 7q21.1              | Sorcin  | 2                     | Calcium-binding; modulates excitation-contraction coupling |
| TCAP | 17q12               | Telethonin | 7                     | Z-disk |
| TNNC1 | 3p21.3–p14.3       | Troponin C | 14                    | Sarcomere |
| TNNI3 | 19q13.4             | Troponin I | 70                    | Sarcomere |
| TNNT2 | 1q32               | Troponin T | 90                    | Sarcomere |
| TPM1 | 15q22.1             | Alpha-tropomyosin | 38                    | Sarcomere; regulates protein degradation |
| TRIM63 | 1p34–p33           | Tripartite motif-containing 63 | 3                     | Sarcomere |
| TTN  | 2q31               | Titin    | 6                     | Sarcomere |
| VCL  | 10q22.1–q23        | Vinculin | 1                     | Sarcomere |

Notes: aHuman genome mutation database (http://www.hgmd.cf.ac.uk/ac/index.php); bNational Center for Biotechnology Information (http://ncbi.nlm.nih.gov/).

Abbreviations: HCM, hypertrophic cardiomyopathy; tRNA, transfer RNA; AMP, adenosine monophosphate; ATP, adenosine triphosphate.

or identified as a cause of HCM; absent from unrelated and ethnic-matched normal controls; protein structure and function is importantly altered (eg, frame shift with truncation); and amino acid sequence change in a region of the protein otherwise highly conserved through evolution (no variation observed) among species.6,24,46 MYH7-R453C, G716R, TNNT2-R92W, and MYBPC3-∆25p mutations can be considered highly pathogenic, as they result in a poorer prognosis with early manifestation of LVH and a higher risk of sudden cardiac death.29,37,47,48

Many substitutions in DNA sequence do not cause disease and are regarded as benign polymorphisms (ie, variants not expected to be deleterious).9,24 Nevertheless, the relevance for causing disease attached to a significant minority of such identified variants remains unclear, even after applying all criteria for pathogenicity.24 As a result, these mutations are designated in genetic test reports into an ambiguous category, ie, variants of uncertain significance (VUS), with virtually no clinical utility for family screening.24

Interfacing a heterogeneous disease such as HCM with the vast genetic variability of the human genome and the high frequency of novel mutations has created unforeseen difficulties in the molecular diagnosis of HCM and its translation to the clinic.24

**Molecular diagnosis**

The molecular diagnosis of HCM, which generally consists of screening for mutations in the sarcomere or other HCM-related genes is usually offered to individuals with the HCM phenotype (in the absence of another disease capable of producing similar cardiac wall thickening) and may identify patients with metabolic storage disorders in whom the clinical presentation and pattern of LVH is similar to HCM, eg, Fabry disease (mutations in GLA) and Danon disease (mutations in PRKAG2 and LAMP2).1,2,24–26

In the event of identification of an HCM-related mutation in a proband, it is recommended to offer genetic testing for first-degree relatives who do not present LVH but may be at risk of developing the disease.24,49 Due to the reduced penetrance of HCM, it is recommended to study at least three generations to help define a case of familial HCM.50 Also, if a relative expresses an HCM phenotype and the pathogenic mutation is identified, the genetic status of other members of the family can be clarified, eliminating anxiety and removing the need for future screening.19 Pretest and post-test genetic counseling is highly recommended for discussion of the risks and options available and future management of the individual.5,6,24,49 Individuals found to carry the family-specific mutation despite an absence of clinical manifestations require longitudinal clinical follow-up that depends on age, phenotype, and genotype.8,24,50 In The Netherlands, a pathogenic mutation can be found in 65% of HCM patients.32,33 This means that systematic predictive testing by means of DNA analysis, so-called cascade testing, is technically possible in these patients’ families. Since it is impossible to know in advance which individuals or families

Roma-Rodrigues and Fernandes

Table 1 (Continued)

| Gene | Chromosomal position | Protein | HCM-associated mutations | Location or function |
|------|----------------------|---------|--------------------------|----------------------|
| RAF1 | 3p25                 | v-Raf-1 murine leukemia viral oncogene homolog 1 | 1                     | Serine/threonine-protein kinase; signal transduction |
| SLC25A3 | 12q23             | Solute carrier family 25, member 3 | 1                     | Phosphate carrier protein (cytosol to mitochondria) |
| SLC25A4 | 4q35               | Solute carrier family 25, member 4 | 2                     | Adenine nucleotide translocator (cytosol/mitochondria) |
| SOS1 | 2p22–p23           | Son of sevenless homolog 1 | 1                     | Guanine nucleotide exchange factor for RAS proteins; signal transduction |
| SRI  | 7q21.1              | Sorcin  | 2                     | Calcium-binding; modulates excitation-contraction coupling |
| TCAP | 17q12               | Telethonin | 7                     | Z-disk |
| TNNC1 | 3p21.3–p14.3       | Troponin C | 14                    | Sarcomere |
| TNNI3 | 19q13.4             | Troponin I | 70                    | Sarcomere |
| TNNT2 | 1q32               | Troponin T | 90                    | Sarcomere |
| TPM1 | 15q22.1             | Alpha-tropomyosin | 38                    | Sarcomere; regulates protein degradation |
| TRIM63 | 1p34–p33           | Tripartite motif-containing 63 | 3                     | Sarcomere |
| TTN  | 2q31               | Titin    | 6                     | Sarcomere |
| VCL  | 10q22.1–q23        | Vinculin | 1                     | Sarcomere |

Notes: aHuman genome mutation database (http://www.hgmd.cf.ac.uk/ac/index.php); bNational Center for Biotechnology Information (http://ncbi.nlm.nih.gov/).

Abbreviations: HCM, hypertrophic cardiomyopathy; tRNA, transfer RNA; AMP, adenosine monophosphate; ATP, adenosine triphosphate.

or identified as a cause of HCM; absent from unrelated and ethnic-matched normal controls; protein structure and function is importantly altered (eg, frame shift with truncation); and amino acid sequence change in a region of the protein otherwise highly conserved through evolution (no variation observed) among species.6,24,46 MYH7-R453C, G716R, TNNT2-R92W, and MYBPC3-∆25p mutations can be considered highly pathogenic, as they result in a poorer prognosis with early manifestation of LVH and a higher risk of sudden cardiac death.29,37,47,48

Many substitutions in DNA sequence do not cause disease and are regarded as benign polymorphisms (ie, variants not expected to be deleterious).9,24 Nevertheless, the relevance for causing disease attached to a significant minority of such identified variants remains unclear, even after applying all criteria for pathogenicity.24 As a result, these mutations are designated in genetic test reports into an ambiguous category, ie, variants of uncertain significance (VUS), with virtually no clinical utility for family screening.24

Interfacing a heterogeneous disease such as HCM with the vast genetic variability of the human genome and the high frequency of novel mutations has created unforeseen difficulties in the molecular diagnosis of HCM and its translation to the clinic.24

**Molecular diagnosis**

The molecular diagnosis of HCM, which generally consists of screening for mutations in the sarcomere or other HCM-related genes is usually offered to individuals with the HCM phenotype (in the absence of another disease capable of producing similar cardiac wall thickening) and may identify patients with metabolic storage disorders in whom the clinical presentation and pattern of LVH is similar to HCM, eg, Fabry disease (mutations in GLA) and Danon disease (mutations in PRKAG2 and LAMP2).1,2,24–26

In the event of identification of an HCM-related mutation in a proband, it is recommended to offer genetic testing for first-degree relatives who do not present LVH but may be at risk of developing the disease.24,49 Due to the reduced penetrance of HCM, it is recommended to study at least three generations to help define a case of familial HCM.50 Also, if a relative expresses an HCM phenotype and the pathogenic mutation is identified, the genetic status of other members of the family can be clarified, eliminating anxiety and removing the need for future screening.19 Pretest and post-test genetic counseling is highly recommended for discussion of the risks and options available and future management of the individual.5,6,24,49 Individuals found to carry the family-specific mutation despite an absence of clinical manifestations require longitudinal clinical follow-up that depends on age, phenotype, and genotype.8,24,50 In The Netherlands, a pathogenic mutation can be found in 65% of HCM patients.32,33 This means that systematic predictive testing by means of DNA analysis, so-called cascade testing, is technically possible in these patients’ families. Since it is impossible to know in advance which individuals or families
will have the greatest advantage from early diagnosis, all index patients who carry an identified mutation should be offered family cascade testing.\textsuperscript{51}

Genetic testing for HCM was initially confined to a few research laboratories that focused on understanding the genetic basis of this disease. In 2003, molecular genetic testing entered the mainstream of the health care system, with automated DNA Sanger sequencing providing more rapid, reliable, and comprehensive molecular diagnosis on a fee-for-service basis.\textsuperscript{24} Due to its well defined chemistry and sequencing precision, Sanger (dideoxy) sequencing has been considered the “gold standard” for clinical genetic testing.\textsuperscript{24,54} Most institutional and commercial laboratories screened 5–10 more frequently mutated sarcomere genes (MYH7, MYBPC3, TNNI3, TNN2, MYL2, TPM1, TNN3, MYL2, MYL3, ACTC, CSR3P, and TCAP).\textsuperscript{51,55} The order of the genes to be screened was MYBPC3 and MYH7, and if no mutations were found, TNNT2, TPM1, TNN13, MYL2, MYL3, ACTC, CSR3P, and TCAP were sequenced in this order.\textsuperscript{51,55} Recently, based on the need to interpret the pathogenic significance of a positive genetic test, Kapplinger et al used Sanger sequencing to annotate genetic variations in the exonic region of nine HCM-associated genes (MYH7, MYLH2, MYLH3, ACTC1, TNNC1, TNN13, TNN2, and TPM1) in a cohort of HCM patients and another of healthy individuals.\textsuperscript{52} With this methodology, it was possible to identify rare non-synonymous variants over-represented in the HCM patient cohort.\textsuperscript{52}

The necessity for electrophoretic separation of DNA fragments is the major obstacle with in Sanger sequencing, increasing experimental time and limiting the number of reactions that can be run in parallel, thus making the technology relatively expensive.\textsuperscript{56,57} For these reasons, this method is used routinely only for sequencing small amounts of DNA fragments.\textsuperscript{58} Sanger sequencing is nevertheless important for cosegregation studies of the supposed causative mutation within HCM families and also as a gold standard validation technique in parallel with novel approaches.\textsuperscript{6,46,56,59–61} The wide genetic heterogeneity of HCM renders Sanger sequencing tedious and too expensive for routine clinical practice,\textsuperscript{60} prompting DNA microarrays as an alternative technique.\textsuperscript{63–65}

These high-throughput techniques allowed simultaneously testing of more samples and inclusion of established HCM-causative genes, phenocopy associated genes, and other genes with lesser evidence of pathogenicity.\textsuperscript{5,24}

The advantages and disadvantages of the methods currently used for molecular screening and diagnosis in HCM are shown in Table 2. The following sections focus on a description of the most recent methods used in HCM screening and diagnosis.

### Screening techniques

Although current clinical guidelines recommend genetic testing in patients with HCM and their relatives, its use in everyday clinical practice has been limited by the cost and complexity of conventional sequencing technologies.\textsuperscript{69,66} Hence, the use of screening techniques that allow analysis of a high number of genes in a shorter period of time, and identifying heteroduplex regions possibly harboring mutations responsible for HCM, is more frequent.\textsuperscript{56,61} After identification of heteroduplex regions, the region of interest must be sequenced by the Sanger technique in order to identify the mutation.\textsuperscript{56,61} Several techniques have been used for HCM diagnostics, consisting firstly in the amplification of the selected gene region by polymerase chain reaction (PCR) followed by differential separation of homoduplexes and heteroduplexes. Using denaturing gradient gel electrophoresis and single-strand conformation polymorphism, the amplicons are separated according to the differing electrophoretic mobility between homoduplexes and heteroduplexes.\textsuperscript{14,67,68} While in denaturing high-performance liquid chromatography, amplicons are separated through the different retention of the denatured amplicons.\textsuperscript{34,67,68}

Screening for mutations using these techniques has proved to be invaluable for identification of mutations in MYBPC3, MYH7, and TNNT2 genes.\textsuperscript{68–75}

High resolution melting has also been used successfully as a screening technique.\textsuperscript{74} High resolution melting is a high-throughput gene variation scanning technique that relies on the differential melting properties of sequences that vary in at least one nucleotide.\textsuperscript{75} For this reason, it is used to identify novel mutations in samples.\textsuperscript{46,56,61} Indeed, this technology was proven effective in screening of mutations in HCM-related genes, providing a closed tube system that reduces the risk of contamination, decreasing analysis time, and requiring no post-PCR sample handling.\textsuperscript{46,56} Moreover, in addition to its effectiveness in screening of novel mutations, this technique may allow identification of mutations on a specific gene under study if the appropriate controls for all the mutations are simultaneously analyzed.\textsuperscript{46,56} Recent results reported by our group\textsuperscript{46,56} and others\textsuperscript{61} have already confirmed the effectiveness of this technique for identification of alterations in HCM patients. Compared with high resolution melting, the large-scale detection of mutations by other screening techniques is more expensive and technically time-consuming.\textsuperscript{61,67}
| Technique              | Major providers           | Advantages                                      | Disadvantages                                                                 | References                      |
|-----------------------|---------------------------|-------------------------------------------------|-------------------------------------------------------------------------------|---------------------------------|
| Sanger sequencing     | Thermo Fisher Scientific  | Accurate                                        | Time-consuming (more than 1 month; total time depends on number of regions analyzed) | *                               |
|                       |                           | Precise                                         | Laborious                                                                     |                                 |
|                       |                           | Important for validation/confirmation proposes   | Expensive                                                                      |                                 |
| dHPLC                 | Transgenomic, Inc.        | Faster than Sanger sequencing (total time depends on number of regions analyzed) | Sensitivity and specificity 87.5% and 97.42%, respectively (compared with Sanger sequencing) | 61,67,104--106                  |
|                       |                           | Optimization laborious                          | Require Sanger sequencing for mutation confirmation                           | 46,56,61,107                    |
| High resolution melting | Hoffman-La Roche Ltd.    | >99% sensitivity and specificity (compared with Sanger sequencing) | Require Sanger sequencing for mutation confirmation                           | 56,75,108                       |
|                       | Qiagen NV                 | Closed-tube genotyping approach, reducing contamination risk | Require Sanger sequencing for mutation confirmation                           |                                 |
|                       | Thermo Fisher Scientific  | Much faster than Sanger sequencing; 3 hours for complete gene scanning (96 or 384 plates; total time depends on number of regions analyzed) |                                |                                 |
|                       | Qiagen NV                 |                                                |                                                                                |                                 |
| iPLEX-MassARRAY       | Sequenom, Inc.            | 48 hours for complete mutation detection (multiplex analysis of more than 10,000 genotypes/384 plate) | Incapable to detect unknown mutations                                         | 61,67,104--106                  |
|                       |                           | Accurate                                        |                                                                                |                                 |
| Next-generation sequencing | Illumina, Inc.            | Allow simultaneous sequencing of large amount of genes | Genome data analysis is time-consuming                                          | 53,60,62,76,81--88              |
|                       | Thermo Fisher Scientific  | Targeted gene panels – limited gene panels allows high depth of coverage for increased sensitivity and specificity | High number of VUS                                                            |                                 |
|                       | Hoffman-La Roche Ltd.     | Higher ability to interpret the findings in a clinical context | Follow-up by Sanger sequencing to fill gaps in the data for regions showing low coverage (eg, GC-rich or repetitive regions) |                                 |
|                       |                           | Allows to run more patient samples per instrument cycle (barcoding and pooling) |                                                                                |                                 |
|                       |                           | Less amount of data and storage requirements     |                                                                                |                                 |

**Note:** *Sanger sequencing is used in all the references provided in this table as the confirmation/validation gold standard technique.

**Abbreviations:** dHPLC, denaturing high-performance liquid chromatography; VUS, variants of uncertain significance.
**Mutation detection**

Mutation detection using the iPLEX MassARRAY matrix-assisted laser desorption/ionization time-of-flight system (Sequenom Inc., San Diego, CA, USA) has been used recently for diagnosis of HCM. In contrast with automated Sanger sequencing, high-throughput techniques such as iPLEX MassARRAY allow rapid and cost-effective testing for a large number of mutations simultaneously. iPLEX MassARRAY involves multiplex primary PCR using outer primers that flank HCM mutation sites followed by a homogeneous mass extend reaction with multiple, single, inner primers that together generate fragments of different mass specific for each genotype (iPLEX). An advantage of iPLEX MassARRAY in comparison with other DNA microarray techniques is its capacity for detecting indels. iPLEX MassARRAY has been successfully used to identify pathogenic mutations, including indels, in more than 30 genes implicated in HCM. Although this technique only detects known mutations, it has been demonstrated to be a high-throughput platform suitable for routine genetic diagnostics, since it allows rapid and relatively inexpensive screening of the most common HCM-related mutations and simultaneous screening of HCM phenocopies. Using an iPLEX MassARRAY system, Brion et al were able to routinely analyze 550 mutations of 16 genes.

**Next-generation sequencing**

Nucleotide-by-nucleotide reading of sequence content by the different next-generation sequencing (NGS) platforms overcomes the limitations of electrophoretic separation and the detection requirements of Sanger sequencing. NGS technologies are now becoming more and more adopted in clinical settings with three main levels of analysis and increasing degrees of complexity, ie, disease-targeted gene panels, exome sequencing, and genome sequencing (covering both coding and noncoding regions). NGS is composed of three major tasks, ie, sample preparation, sequencing, and data analysis. The workflow begins with extraction of genomic DNA from patient samples with targeted panels and exome sequencing requiring enrichment strategies to focus on a subset of genomic targets (usually short DNA fragments [100–500 base pairs] flanked by platform-specific adapters). However, GC-rich and repetitive regions within the human genome are still not amenable to be covered by NGS due to sequence complexity and require follow-up by Sanger sequencing to fill the gaps in the data. The multiple commercial sequencing platforms developed (Table 2) are able to sequence millions of DNA fragments in parallel, and the different sequencing chemistries result in differences in total sequence capacity, sequence read length, sequence run time, and the final quality and accuracy of the data. Chemistries include sequencing by synthesis or sequencing by ligation with reversible terminators, bead capture, and ion sensing.

In addition to sequence identification, NGS provides information on variation in the copy number of alleles within the sequenced transcripts. However, the huge amount of information generated is simultaneously the greatest advantage and greatest disadvantage of NGS. A single sequencing experiment generates millions of sequence datasets that need to be analyzed. For this reason, clinical application of NGS in HCM has increasingly involved targeted resequencing of genomic subregions, often called “subgenomes”, as a strategy to reduce the amount of data generated by sequencing and facilitate the data analysis. With this methodology, regions of interest are selected by amplification-based methods, such as targeted PCR enrichment or oligonucleotide capture-based methods using either solid surface arrays or in-solution DNA fragment capture. Compared with exome sequencing and genome sequencing, targeted gene panels with a limited gene number allow: a high depth of coverage, with increasing sensitivity and specificity; a high capacity to interpret the findings in a clinical context; running of more patient samples per cycle (barcoding and pooling); less amount of data generated; and less storage requirements. The coverage and cost of exome sequencing will be between those of targeted gene panels and genome sequencing; nevertheless, the analytical sensitivity of exome sequencing may be lower than the sensitivity of most targeted gene panels, since a high number of exons in known disease-associated genes may lack sufficient coverage to make a sequence call, and in these cases, follow-up by Sanger sequencing to fill gaps in the data is impractical and expensive. In the last 5 years, several of these NGS enrichment methods for genotyping HCM-related mutations have been tested, and were generally observed to provide faster, accurate, and efficient clinical genetic analysis.

NGS data have emerged in HCM, suggesting that double (or triple) or compound pathogenic mutations can be associated with more severe disease expression and an adverse prognosis (eg, heart failure or sudden death, even in the absence of conventional risk markers), with several implications for genetic counselling. While it is possible that multiple mutations will prove to be prognostic markers or arbiters of ambiguous risk profiles, the current evidence...
is preliminary and prospective long-term studies in large populations are required.24 Nevertheless, a major dilemma concerning NGS data for interpreting test results in HCM lies in distinguishing pathogenic mutations from variants of uncertain clinical significance (VUS) or rare nonpathogenic variants.89 This issue has become particularly challenging because the reduced cost of NGS technology now allows comprehensive DNA sequencing of the exome and even the whole genome.84,89,91 Although providing increased scientific insight, NGS substantially increases the recognition of VUS, creating further ambiguity in test reports.24,92,93 Targeted resequencing allows a reduction in the number of VUS identified while increasing the depth of coverage when compared with exome sequencing and genome sequencing.76 Lopes et al, using their targeted NGS strategy, identified a large number of rare non-synonymous sequence variants in non-sarcomeric genes (such as RYR2, ANK2, CAV3, and SCN5A) that may be potential phenotype modifiers in HCM and could explain the genetic heterogeneity of the disease.52 Understanding the clinical significance of these novel variants remains a challenge, reinforcing the need for generally accepted guidelines for interpreting VUS.6,24,82,92,93 The American College of Medical Genetics and Genomics has developed laboratory standards and guidelines for NGS to ensure quality results and more consistent interpretation and reporting of variants found using these technologies.76

Therefore, application of NGS to HCM stands at a crossroads. If genetic testing is to evolve and have a more substantial role in the management of patients with HCM, future efforts should focus on clarifying precisely the pathogenicity of the substantial number of novel variants that are presently recognized and associated with the clinical heterogeneity of HCM and those that will inevitably be identified by new molecular techniques.

Therapeutics for hypertrophic cardiomyopathy

Current treatments

Current therapeutics for HCM patients depend on clinically observed phenotypes and are based on alleviation of symptoms.5,94 The pharmacotherapy applied in HCM is based on β-blockers, calcium channel blockers, and disopyramide. β-blockers improve the myocardial oxygen supply by inactivation of myocardial contractile proteins, and thereby alleviate left ventricular outflow.5,8,94,95 Calcium channel blockers used in HCM include verapamil and diltiazem.5,95 Verapamil acts to decrease the resting outflow gradients, thereby improving diastolic function;9,95 however, the secondary effects of this agent include vasodilation, hypotension, and pulmonary edema, limiting its use to second-line therapy.9,95 Disopyramide is an antiarrhythmic agent that exerts a negative inotropic effect on myocytes by altering sodium–calcium exchange.5,95 However, disopyramide is a third-line therapy and should be given in conjunction with β-blockers and calcium channel blockers.8,95

Only 5% of HCM patients require invasive therapies for symptom control.8,96 Surgical myectomy and alcohol ablation are generally used to relieve left ventricular obstruction in severely symptomatic patients.5,5,8 On the other hand, implantation of an internal cardioverter defibrillator is generally considered for termination of life-threatening arrhythmias, avoiding the possibility of sudden cardiac death and hence extending the lifespan of the patient.3 HCM patients with atrial fibrillation are generally treated with anticoagulation agents to avoid thromboembolism, and can also be considered for pulmonary vein isolation, pacemaker implantation, or a surgical Maze procedure.8

Despite the advantages of early detection of HCM, there is currently no evidence that this will change the course of the disease.95 Indeed, regardless of improvement in quality of life for HCM patients, current pharmacological therapy is not able to overcome the effects of HCM-induced myocardial disorders and cannot improve the long-term prognosis.95 However, given that myocardial dysfunction occurs before development of LVH, and does not necessarily result in symptomatic features, early administration of β-blockers and calcium channel blockers in asymptomatic patients may help to prevent the onset of symptoms and/or reduce the risk of sudden cardiac death.9,20

Tissue engineering and regenerative medicine

The major limitations for the design of new drugs for HCM relate to the lack of in vitro models of human cardiac disorders that accurately reflect disease phenotypes, as well as the genomic differences between humans and the mouse, the most common genetic animal model used for the study of human cardiovascular disorders.97,98 Use of scaffolds that mimic the composition, structure, and biomechanics of the native human heart, together with differentiation of pluripotent stem cells into cardiomyocytes in HCM patients, may aid a deeper understanding of the mechanisms that lead to onset of the disease, and possibly a better understanding of the genotype-phenotype correlation.98,99 Moreover, these
systems can be used to screen accurate therapeutic drugs for the pathology induced by particular HCM-related mutations, allowing insights into drug efficiency, safety, and mode of action.99,100

One of the most interesting possibilities in cardiac regenerative medicine is the reprogramming of cardiac fibroblasts to become beating cardiomyocytes.101 This has special importance for HCM patients, since there is a possibility that early reprogramming of fibroblasts into myocytes would reduce the extent of myocardial fibrosis and consequently decrease the risks of development of other pathological HCM-related conditions and sudden cardiac death. Several studies performed in the last decade suggest that such reprogramming is possible, but that it is technically challenging and relatively inefficient, so further studies are needed to achieve the possibility of reprogramming in vivo.101 After optimization of this procedure, nanotherapeutics could be used to target cardiac fibroblasts in the patient using nanoparticles containing miRNAs and the transcription factors that need to be reprogrammed for generation of cardiomyocytes.101

The rapid progress in nanotechnology is changing the foundations for diagnosis, treatment, and prevention of cardiovascular disease. Nanotechnology-derived structures offer “three-in-one functions as imaging systems, target probes, and therapeutic carriers, and are capable of delivering considerable amounts of a drug to cells in a targeted directed manner, so are being developed for use in cardiovascular disease.102 Several ligand-target therapeutic strategies are being developed to overcome the current limitations of conventional drugs and provide additional tools for therapy.102 Nanotechnology offers a wealth of safe tools for the treatment and diagnosis of cardiovascular disease, such as targeted devices with unique therapeutic properties that, because of their small size, can pass biological barriers and deliver multiple therapeutic agents directly to cardiomyocytes.102 Use of molecularly targeted nanovectors affords at least four potential advantages over conventional therapy, and ideally, a delivery system ought to: deliver much greater therapeutic payloads per target; carry multiple, potentially different targeted agents, thereby enhancing selectivity; integrate a means to bypass biological barriers; and enable colocalized delivery of multiple agents, resulting in targeted combination therapy.102

Other “nanotools” are focused on the development of a safe, efficient, specific, and non-pathogenic vehicle for gene delivery.103 Therapeutic and diagnostic agents can be encapsulated, covalently attached, or adsorbed onto such nanocarriers.103 These approaches can easily overcome drug solubility issues, particularly given that large proportions of new drug candidates emerging from high-throughput drug screening initiatives are not water-soluble.103

**Conclusion and future directions**

It is well established that HCM is a genetically heterogeneous disease, resulting from mutations occurring mainly in sarcomere genes. However, new HCM-related mutations are continuously being revealed, and much more are still to be discovered.9 The dramatic clinical outcomes of HCM, including sudden cardiac death in younger people, including trained athletes, makes early and accurate diagnosis of the pathology essential. Recent advances in the molecular biology field with novel and rapidly evolving strategies for generating genetic data using next-generation technologies opens up the possibility of defining new genes responsible for HCM. Nevertheless, these exome and whole-genome sequencing approaches also reveal a multitude of novel variants and VUS for which clinical relevance is uncertain. The complexity of the information obtained by NGS analysis is being diminished by fractionation of the genome into subgenomes, making this platform one of the most promising for clinical diagnosis of HCM. Nevertheless, future efforts should focus on clarifying more precisely the pathogenicity of the substantial number of novel variants presently known and those that will inevitably be identified by new molecular techniques. It is imperative to create joint collaborations between academia, commercial testing laboratories, and hospitals to promote the exchange of genetic information and to develop standardized mutation classification approaches that allow translation into patient care.

Therapeutics for HCM patients are mainly based on symptom relief, partly due to difficulties in cardiomyocyte cell culture and a lack of suitable animal models. Although in its infancy, cardiac tissue engineering seems to be promising in terms of providing a deeper understanding of the biological mechanisms inherent to HCM and being able to develop new therapeutic approaches for cardiovascular regeneration. Moreover, regenerative medicine together with nanotechnology may improve the therapeutics available for HCM patients by allowing early regeneration of the heart, even in asymptomatic subjects.

**Acknowledgment**

We thank the Fundação para a Ciência e a Tecnologia/Ministério da Educação e Ciência (FCT/MEC) for financial
support via PTDC/CVT-EP1/4651/2012 and PEst-OE/QUI/UI0100/2013.

Disclosure
The authors report no conflicts of interest in this work.

References
1. Maron BJ, Towbin JA, Thieme G, et al. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation. 2006;113:1807–1816.

2. Elliott P, Andersson B, Arbustini E, et al. Classification of the cardiomyopathies: a position statement from the European Society of Cardiology Working Group on myocardial and pericardial diseases. Eur Heart J. 2008;29:270–276.

3. Thieme G, Corrado D, Basso C. Cardiomyopathies: is it time for a molecular classification? Eur Heart J. 2004;25:1772–1775.

4. Khouzam RN, Naidu SS. Muscle dysfunction in hypertrophic cardiomyopathy: is it time for a molecular classification? Circulation. 2003;108:169–172.

5. Poggesi C, Ho CY. Muscle dysfunction in hypertrophic cardiomyopathy: what is needed to move to translation? J Muscle Res Cell Motil. 2014;35:37–45.

6. Santos S, Freitas AT, Fernandes AR. Overview of HCM genomics and transcriptomics: molecular tools in HCM assessment for application in clinical medicine. Cardiovascular Disease II. iConcept Press. Available from: http://www.iconceptpress.com/books/cardiovascular-disease-ii/. In press 2014.

7. Thiene G, Corrado D, Basso C. Cardiomyopathies: is it time for a molecular classification? Eur Heart J. 2004;25:1772–1775.

8. Kouzum RN, Naidu SS. Current status and future perspectives on alcohol septal ablation for hypertrophic obstructive cardiomyopathy. Curr Cardiol Rep. 2014;16:478.

9. Efthimiadis GK, Pagourelas ED, Gossios T, Zegkos T. Hypertrophic cardiomyopathy in 2013: current speculations and future perspectives. World J Cardiol. 2014;6:26–37.

10. Santos S, Freitas AT, Fernandes AR. Overview of HCM genomics and transcriptomics: molecular tools in HCM assessment for application in clinical medicine. Cardiovascular Disease II. iConcept Press. Available from: http://www.iconceptpress.com/books/cardiovascular-disease-ii/. In press 2014.

11. Poggesi C, Ho CY. Muscle dysfunction in hypertrophic cardiomyopathy: what is needed to move to translation? J Muscle Res Cell Motil. 2014;35:37–45.

12. Enriquez AD, Goldman ME. Management of hypertrophic cardiomyopathy. Ann Glob Health. 2014;80:35–45.

13. Bos JM, Towbin JA, Ackerman MJ. Diagnostic, prognostic, and therapeutic implications of genetic testing for hypertrophic cardiomyopathy. J Am Coll Cardiol. 2013;62:449–457.

14. Rowin EJ, Maron MS. The ever expanding spectrum of phenotypic diversity in hypertrophic cardiomyopathy. Am J Cardiol. 2013;112:463–464.

15. Dhandapani PS, Sadayappan S, Xue Y, et al. A common MYBPC3 (cardiac myosin binding protein C) variant associated with cardiomyopathies in South Asia. Nat Genet. 2009;41:187–191.

16. Alders M, Jongbloed R, Deelen W, et al. The 2373insG mutation in the MYBPC3 gene is a founder mutation, which accounts for nearly one-fourth of the HCM cases in the Netherlands. Eur Heart J. 2003;24:1848–1853.

17. Andersen PS, Havndrup B, Bundgaard H, et al. Genetic and phenotypic characterization of mutations in myosin-binding protein C (MYBPC3) in 81 families with familial hypertrophic cardiomyopathy: total or partial haploinsufficiency. Eur J Hum Genet. 2004;12:673–677.

18. Jääskeläinen P, Miettinen R, Kärkkäinen P, Kuusisto J. Genetics of hypertrophic cardiomyopathy: X marks the spot. Circ Cardiovasc Genet. 2010;3:528–530.

19. Hartmannova H, Kubanek M, Sramko M, et al. Isolated X-linked hypertrophic cardiomyopathy caused by a novel mutation of the four-and-a-half LIM domain 1 gene. Circ Cardiovasc Genet. 2013;6:543–551.

20. Ho CY. Hypertrophic cardiomyopathy: preclinical and early phenotype. J Cardiovasc Transl Res. 2009;2:462–470.

21. Spirito P, Autore C, Formisano F, et al. Risk of sudden death and outcome in patients with hypertrophic cardiomyopathy with benign presentation and without risk factors. Am J Cardiol. 2011;113:1550–1555.

22. Nishimura RA, Ommen SR. Hypertrophic cardiomyopathy: the search for obstruction. Circulation. 2006;114:2200–2202.

23. Gerah BJ, Maron BJ, Bonow RO, et al. ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy. J Thorac Cardiovasc Surg. 2011;142:e153–e203.

24. Maron BJ, Maron MS, Semsarian C. Genetics of hypertrophic cardiomyopathy after 20 years: clinical perspectives. J Am Coll Cardiol. 2012;60:705–715.

25. Jacoby DL, DePasquale EC, McKenna WJ. Hypertrophic cardiomyopathy: diagnosis, risk stratification and treatment. CMAJ. 2013;185:127–134.

26. Sankaranarayanan R, Fleming DJ, Garratt CJ. Mimics of hypertrophic cardiomyopathy – diagnostic clues to aid early identification of phenocopies. Arrhythmia and Electrophysiology Review. 2013;2:36–40.

27. Semsarian C, Ingles J. Expanding the genetic spectrum of hypertrophic cardiomyopathy: X marks the spot. Circ Cardiovasc Genet. 2013;6:528–530.

28. Groeneweg YL, van Hemert VM, Middelkoop E, et al. Lost function but retained binding by the sarcomeric protein myomesin in familial hypertrophic cardiomyopathy. Circulation. 2008;118:194–202.
41. Gajendrarao P, Krishnamoorthy N, Kassem HS, et al. Molecular modeling of disease causing mutations in domain C1 of cMyBP-C. *PLoS One*. 2013;8:e69206.

42. Bos JM, Ackerman MJ. Z-disk genes in hypertrophic cardiomyopathy: stretching the cardiomyopathies? *J Am Coll Cardiol*. 2010;55:1136–1138.

43. Watkins H, McKenna WJ, Thierfelder L, et al. Mutations in the genes for cardiac troponin T and alpha-tropomyosin in hypertrophic cardiomyopathy. *N Engl J Med*. 1995;332:1058–1064.

44. Ho CY. Hypertrophic cardiomyopathy. *Heart Fail Clin*. 2010;6:141–159.

45. Niimura H, Patton KK, McKenna WJ, et al. Sarcomere protein gene mutations in hypertrophic cardiomyopathy of the elderly. *Circulation*. 2002;105:446–451.

46. Santos S, Marques V, Pires M, et al. High resolution melting: improvements in the genetic diagnosis of hypertrophic cardiomyopathy in a Portuguese cohort. *BMC Med Genet*. 2012;13:17.

47. Ackerman MJ, VanDriest SL, Ommen SR, et al. Prevalence and age-dependence of malignant mutations in the beta-myosin heavy chain and troponin T genes in hypertrophic cardiomyopathy: a comprehensive outpatient perspective. *J Am Coll Cardiol*. 2002;39:2042–2048.

48. Landstrom AP, Ackerman MJ. Mutation type is not clinically useful in predicting prognosis in hypertrophic cardiomyopathy. *Circulation*. 2010;122:2441–2449.

49. Ho CY. Genetics and clinical destiny: improving care in hypertrophic cardiomyopathy. *Circulation*. 2010;122:2430–2440.

50. Hershberger RE, Lindenfeld J, Mestroni L, et al. Genetic evaluation of cardiomyopathy – a Heart Failure Society of America practice guideline. *J Card Fail*. 2009;15:83–97.

51. van Langen IM, Arens Y, Baars H, et al; ICIN Working Group on Hereditary Heart Diseases. Genetic diagnostics and genetic counseling in hypertrophic cardiomyopathy (HCM). *Neth Heart J*. 2010;18:144–159.

52. Kapplinger JD, Landstrom AP, Bos JM, et al. Distinguishing hypertrophic cardiomyopathy-associated mutations from background genetic noise. *J Cardiovasc Transl Res*. 2014;7:347–361.

53. Dames S, Durttschi J, Geiersbach K, Stephens J, Voelkerding KV. Population genetic analysis of the MYBPC3 gene. *BMC Med Genet*. 2008;9:95.

54. Millat G, Bouvagnet P, Chevalier P, et al. Development of a high-throughput sequencing for Mendelian cardiac disorders. *PLoS One*. 2013;8:e67087.
84. Meder B, Haas J, Keller A, et al. Targeted next-generation sequencing for the molecular genetic diagnostics of cardiomyopathies. Circ Cardiovasc Genet. 2011;4:110–122.
85. Wheeler M, Pavlovic A, DeGoma E, Salisbury H, Brown C, Ashley EA. A new era in clinical genetic testing for hypertrophic cardiomyopathy. J Cardiovasc Transl Res. 2009;2:381–391.
86. Millat G, Chanavat V, Rousson R. Evaluation of a new NGS method based on a custom AmpliSeq library and Ion torrent PGM sequencing for the fast detection of genetic variations in cardiomyopathies. Clin Chim Acta. 2014;433C:268–271.
87. Bick AG, Flannick J, Ito K, et al. Burden of rare sarcomere gene variants in the Framingham and Jackson Heart Study cohorts. Am J Hum Genet. 2012;91:513–519.
88. Herman DS, Lam L, Taylor MR, et al. Truncations of titin causing dilated cardiomyopathy. N Engl J Med. 2012;366:619–628.
89. Tester DJ, Ackerman MJ. Genetic testing for potentially lethal, highly treatable inherited cardiomyopathies/channelopathies in clinical practice. Circulation. 2011;123:1021–1037.
90. Mestroni L, Taylor MR. Hearing the noise: the challenges of human genome variation in genetic testing. J Am Coll Cardiol. 2011;57:2328–2329.
91. The 1000 Genomes Project Consortium. A map of human genome variation from populations – scale sequencing. Nature. 2010;467:1061–1073.
92. Watkins H. Assigning a causal role to genetic variants in hypertrophic cardiomyopathy. Circ Cardiovasc Genet. 2013;6:2–4.
93. Das K J, Ingles J, Bagnall RD, Semsarian C. Determining pathogenicity of genetic variants in hypertrophic cardiomyopathy: importance of periodic reassessment. Genet Med. 2014;16:286–293.
94. McKenna WJ, Behr ER. Hypertrophic cardiomyopathy: management, risk stratification, and prevention of sudden death. Heart. 2002;87:169–176.
95. Hamada M, Ikeda S, Shigematsu Y. Advances in medical treatment of hypertrophic cardiomyopathy. J Cardiol. 2014;64:1–10.
96. Efthimiadis GK, Pitsis A, Pagourelas ED, et al. Surgical septal myectomy for hypertrophic cardiomyopathy in Greece: a single-center initial experience. Hellenic J Cardiol. 2014;55:132–138.
97. Moretti A, Laugwitz KL, Dorn T, Sinnecker D, Mummery C. Pluripotent stem cell models of human heart disease. Cold Spring Harb Perspect Med. 2013;3:a014027.
98. Garbern JC, Mummery CL, Lee RT. Model systems for cardiovascular regenerative biology. Cold Spring Harb Perspect Med. 2013;3:a014019.
99. Vunjak-Novakovic G, Eschenhagen T, Mummery C. Myocardial tissue engineering: in vitro models. Cold Spring Harb Perspect Med. 2014;4:a014076.
100. Liang P, Du J. Human induced pluripotent stem cell for modeling cardiovascular diseases. Regenerative Medicine Research. 2014;2:4.
101. Yi BA, Mummery CL, Chien KR. Direct cardiomyocyte reprogramming: a new direction for cardiovascular regenerative medicine. Cold Spring Harb Perspect Med. 2013;3:a014050.
102. Kumar N, Kumar R. Nanomedicine for treatment of cardiovascular diseases. In: Nanotechnology and Nanomaterials in the Treatment of Life-threatening Diseases. Waltham, MA, USA: Elsevier; 2014.
103. Wagner V, Dullaart A, Bock AK, Zweck A. The emerging nanomedicine landscape. Nat Biotechnol. 2006;24:1211–1217.
104. Bahrudin U, Mizuta E, Ariani MD, Nindita Y, Hisatome I. Sensitivity and specificity of denaturing HPLC to detect MYBPC3 gene mutations in hypertrophic cardiomyopathy. Yonago Acta Med. 2009;52:121–125.
105. Bos JM, Poley RN, Ny M, et al. Genotype-phenotype relationships involving hypertrophic cardiomyopathy-associated mutations in titin, muscle LIM protein, and telethonin. Mol Genet Metab. 2006;88:78–85.
106. van Driest SL, Jaeger MA, Ommen SR, et al. Comprehensive analysis of the beta-myosin heavy chain gene in 389 unrelated patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2004;44:602–610.
107. Chen D, Wang YY, Chuai ZR, et al. High-resolution melting analysis for accurate detection of BRAF mutations: a systematic review and meta-analysis. Sci Rep. 2014;4:4168.
108. Allegue C, Gil R, Blanco-Verea A, et al. Prevalence of HCM and long QT syndrome mutations in young sudden cardiac death-related cases. Int J Legal Med. 2011;125:565–572.